Study risk assessment of Japan Clinical Oncology Group (JCOG) clinical trials using the European Organisation for Research and Treatment of Cancer (EORTC) study risk calculator
ConclusionsJCOG conducts central monitoring and site visit audit with sampling source data verification for every trial, which are almost compatible with the way in EORTC for the medium risk group. Because most of the JCOG studies were classified into low or medium risk group, the intensity of monitoring and audit in JCOG was considered as reasonable even from the EORTC perspective. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - September 6, 2019 Category: Cancer & Oncology Source Type: research

Incidence rates of esophageal cancer in the world from the Cancer Incidence in Five Continents XI
In order to make of recent cancer incidence rates between Japan and other countries, we abstracted the age-standardized incidence rates (ASRs) by three age categories (0 –59, 60–74 and 75+) from the Cancer Incidence in Five Continents Vol. XI (CI5) (1). International Agency for Research on Cancer provides the CI5 databases on the incidence of cancer recorded by cancer registries (regional and national) worldwide. We used ASRs from the following cancer registries: the United States of America, Beijing in China, Mumbai in India, Hiroshima and Osaka in (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - September 6, 2019 Category: Cancer & Oncology Source Type: research

In this issue
(Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - September 6, 2019 Category: Cancer & Oncology Source Type: research

PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy
Discussion of gene alterations other thanBRCA include the results of multiple gene panels studying homologous recombination repair deficiency genes and cancer susceptibility genes, and influences of these alterations on efficacy of PARP inhibitors and cancer susceptibility. Discussions of HRD include the results of phase three trials using HRD assay, the definition of HRD assays, and the latest assays. Discussions of combinations include early phase trial results and ongoing trials combining PARP inhibitors with immune checkpoint inhibitors, anti-angiogenic agents, and triplets. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 26, 2019 Category: Cancer & Oncology Source Type: research

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
AbstractA pilot study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer has been started in Korea. Archival tumor samples were tested for HRD and PD-L1 status. Treatment arms will be allocated according to the test results. For HRD+ patients, we tested the synergistic effects of olaparib and other agents; treatment arms will randomly be allocated. (Arm 1: olaparib and cediranib; Arm 2: olaparib and durvalumab). For HRD- patients, we tested the role of biomarker-driven immunotherapy according to PD-L1 expression (Arm 3: durvalumab and chemotherapy in patients with high PD-L1 e...
Source: Japanese Journal of Clinical Oncology - June 26, 2019 Category: Cancer & Oncology Source Type: research

Incidence rates of liver cancer in the world from the Cancer Incidence in Five Continents XI
(Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 20, 2019 Category: Cancer & Oncology Source Type: research

A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition)
AbstractA number of major modifications were made to the classification of head and neck carcinomas in the eighth edition of the American Joint Committee on Cancer, Cancer Staging Manual and Union for International Cancer Control TNM classification of Malignant Tumors. These modifications were aimed at improving the prognosis prediction accuracy of the system. In this article, we review the new edition of the TNM classification system. Among the several changes in the new system, a separate algorithm for p16-positive oropharyngeal carcinoma was included, as were new chapters on ‘Head and Neck Skin Carcinoma’ an...
Source: Japanese Journal of Clinical Oncology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Immunomodulatory drugs in the treatment of multiple myeloma
AbstractThe prognosis of multiple myeloma was quite poor in the last century, but it has significantly improved with the incorporation of novel agents, immunomodulatory drugs (IMiDs) and proteasome inhibitors. Thalidomide was first developed as a sedative in 1950s, but it was withdrawn from the market because of teratogenicity. In 1990s, however, thalidomide received attention due to the discovery of its anticancer potential derived from antiangiogenic and immunomodulatory activities, and its therapeutic effect on myeloma. In 2006, the U.S. Food and Drug Administration approved the use of thalidomide under strict control f...
Source: Japanese Journal of Clinical Oncology - June 12, 2019 Category: Cancer & Oncology Source Type: research

Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation
AbstractExon 18 delE709_T710insD is an extremely rare mutation inepidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC); the efficacy of EGFR tyrosine kinase inhibitors against this mutation remains unclear. In this case report, we report a case of NSCLC harboringEGFR exon 18 delE709_T710insD that was not detected by a commercially available assay, but was detected by a next-generation sequencing cancer panel. A 56-year old female patient with advanced NSCLC was diagnosed asEGFR-mutation-negative using the PNAClamp method.ALK rearrangement was also absent and she received cytotoxic chemotherapies. Cl...
Source: Japanese Journal of Clinical Oncology - June 12, 2019 Category: Cancer & Oncology Source Type: research

Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient
malignant pleural mesotheliomaimmune checkpoint inhibitornivolumabencephalitisanti-Ma2-antibody (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 12, 2019 Category: Cancer & Oncology Source Type: research

Curative thoraco-systemic therapy plus local treatment to the brain for extensive disease-small-cell lung cancer with metastasis only to the brain
In conclusion, ED-SCLC with metastasis limited to the brain could be treated with curative intent. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 28, 2019 Category: Cancer & Oncology Source Type: research

The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy
AbstractThe advancement of cancer genomics research due to the development of next generation sequencing technologies is going to bring the promise of cancer precision medicine, in turn revolutionizing cancer detection and treatment. In this review, we will discuss the possible road map for implementation of cancer precision medicine into the clinical practice by mainly focusing on the role of liquid biopsy, particularly circulating tumor DNA, as a potential tool for cancer screening, selection of an appropriate drug(s), surveillance of minimal residual diseases, and early detection of recurrence. We will also review the c...
Source: Japanese Journal of Clinical Oncology - May 28, 2019 Category: Cancer & Oncology Source Type: research

Complete resolution of bone metastases with pembrolizumab
(Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 28, 2019 Category: Cancer & Oncology Source Type: research

The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
ConclusionsIn this study, the effect of ICI rechallenge was limited. Careful consideration of the administration of ICI rechallenge is necessary. This report involved a small number of cases, so further large prospective studies are warranted to confirm the efficacy of ICI rechallenge and to investigate predictive markers to identify a patient population in which ICI rechallenge is effective. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 15, 2019 Category: Cancer & Oncology Source Type: research

Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202)
ConclusionsS-1 plus cisplatin in combination with bevacizumab met the primary endpoint in patients with advanced NSq-NSCLC. RR was anticipated to be high with acceptable toxicities. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 9, 2019 Category: Cancer & Oncology Source Type: research

Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy
AbstractBackgroundInternational Metastatic Renal Cell Carcinoma Database Consortium model predicts the outcomes of metastatic renal cell carcinoma stratified into favorable, intermediate, and poor risk groups (FG, IG, and PG, respectively), with approximately 50% of patients being classified as IG. We aimed to generate better risk model based on the sub-classification of IG.MethodsWe analyzed records of 213 consecutive patients receiving molecular targeted therapy. Age, gender, histology, type of initial molecular targeted therapy, serum laboratory data, previous nephrectomy and immunotherapy, and metastatic sites were use...
Source: Japanese Journal of Clinical Oncology - May 7, 2019 Category: Cancer & Oncology Source Type: research

A preliminary study of the effectiveness of cancer communication skills training for interdisciplinary staff
This study utilized a quasi-experimental design. The participants were 124 oncology professionals who participated in cancer CST. These 124 professionals included a group of 65 doctors and a group of 59 interdisciplinary professionals, both of which received the same CST. After the participants have received CST, the changes in their disease disclosure skills were evaluated.ResultsSignificant pretest-posttest differences were observed in the overall truth-telling scores for both groups (doctors:t = 6.94,P
Source: Japanese Journal of Clinical Oncology - May 7, 2019 Category: Cancer & Oncology Source Type: research

A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patients
AbstractBackgroundOur previous study reported a method for determiningMYCN gene amplification (MNA) status using cell-free DNA in serum. We prospectively analyzed the serum MNA status using sera obtained before the initial diagnosis from patients with neuroblastoma and evaluated the utility of this method.MethodsEighty patients were enrolled in the study. The serumMYCN/NAGK ratio was assessed for all cases.ResultsFifteen cases showed serum MNA, while 65 did not. Of the 80 total patients, tumor samples for a genetic analysis were not obtained from 27 due to the patients ’ condition or other reasons. For the 43 of 80 c...
Source: Japanese Journal of Clinical Oncology - May 4, 2019 Category: Cancer & Oncology Source Type: research

Use of intensity-modulated radiation therapy for nasopharyngeal cancer in Japan: analysis using a national database
ConclusionsIMRT has not been widely adopted in Japan for treating NPC. Barriers for adopting its use should be identified to close the gap between the standard and actual medical practice in Japan. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - April 27, 2019 Category: Cancer & Oncology Source Type: research

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan
ConclusionsCabazitaxel plus granulocyte colony-stimulating factor is safe and effective for Japanese patients with metastatic castration-resistant prostate cancer who have previously progressed on docetaxel.Clinical trial registration: ClinicalTrials.gov (NCT02441894). (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - April 26, 2019 Category: Cancer & Oncology Source Type: research

The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma
ConclusionsExpression of histone deacetylase 5, 7 and 9 is a potential prognostic marker in uterine leiomyosarcoma when combined with pathologically relevant prognostic factors (p53 and histological subtype). This prevalent and strong histone deacetylase expression warrants further study in well-designed investigations of histone deacetylases as therapeutic targets in uterine leiomyosarcoma. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - April 26, 2019 Category: Cancer & Oncology Source Type: research

Issues associated with medical tourism for cancer care in Japan
ConclusionMedical tourism raises various issues. Institutional and medical staff should be adequately prepared by developing working systems. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - April 26, 2019 Category: Cancer & Oncology Source Type: research

Mesenchymal –epithelial transition gene amplification and protein overexpression in stage IV pulmonary adenocarcinoma
ConclusionsAlthoughMET amplification-positive tumor is considered aggressive, our results suggest that it has a more favorable prognosis than amplification-negative cases in stage IV pulmonary adenocarcinoma with medical treatment. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - April 26, 2019 Category: Cancer & Oncology Source Type: research

Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy achieved the equivalent survival compared with concurrent chemoradiotherapy in cervical cancer patients with intermediate-risk
ConclusionsPostoperative adjuvant CT+ICRT treatment achieved equivalent 3-year DFS and OS but low complication rate compared to CCRT treatment in early stage cervical cancer patients with intermediate-risk. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - April 24, 2019 Category: Cancer & Oncology Source Type: research

Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings
AbstractObjectivePost-marketing surveillance (PMS) was performed in Japan to obtain information on the safety and efficacy of crizotinib.MethodsTarget patients included almost all patients with anaplastic lymphoma kinase-positive non-small cell lung cancer who were administered crizotinib. The observation period was 52 weeks. In the present study, we focused on the treatment status and safety of crizotinib therapy and analyzed the real-world data obtained by this PMS (ClinicalTrials.gov: NCT01597258).ResultsThe safety analysis set included 2028 Japanese patients, and more than half of the patients (56.4%) were nonsmokers. ...
Source: Japanese Journal of Clinical Oncology - April 22, 2019 Category: Cancer & Oncology Source Type: research

Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program
AbstractObjectivesPerinephric fat invasion (PFI) of renal cell carcinoma (RCC) is known to be associated with adverse pathological features and poor prognosis. We analyzed these associations using a sub-group of the RCC registry of The Cancer Registration Committee of the Japanese Urological Association.MethodsThe study cohort of 2998 non-metastatic cases was retrieved from RCC registry (3648 in total). We compared clinicopathological characteristics of cases with PFI (n = 256) and without PFI (n = 2742), and investigated the impact of PFI on cancer-specific survival using univariate and multivariate analyses.ResultsCompar...
Source: Japanese Journal of Clinical Oncology - April 12, 2019 Category: Cancer & Oncology Source Type: research

Effects of adjuvant radiation therapy on survival for patients with resected primary tracheal carcinoma: an analysis of the National Cancer Database
ConclusionsAdjuvant RT was not significantly associated with OS for patients with resected PTC in this analysis. Surgical margin status and tumor histology were associated with receiving adjuvant RT. Further investigations including prospective registry studies capturing radiation technique and treatment volumes are needed to better define which patients with resected PTC may benefit from adjuvant RT. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - April 12, 2019 Category: Cancer & Oncology Source Type: research

Long-term outcome, relapse patterns, and toxicity after radiotherapy for orbital mucosa-associated lymphoid tissue lymphoma: implications for radiotherapy optimization
ConclusionLow-dose RT with proper lens shielding is an appropriate treatment for orbital MALToma in terms of high disease control rate and acceptable morbidity. However, lower RT dose may be attempted to further reduce toxicity while maintaining excellent outcomes. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - April 11, 2019 Category: Cancer & Oncology Source Type: research

Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis
AbstractBackground and aimThe impact of transarterial chemoembolization (TACE) and preventive antiviral therapy on the occurrence of hepatitis B virus (HBV) reactivation and subsequent hepatitis remains controversial. This meta-analysis aimed to evaluate the effect of TACE and preventive antiviral therapy on the risk of HBV reactivation and subsequent hepatitis. Meanwhile, we explored the role of HBeAg status in HBV reactivation after TACE.MethodsWe performed this meta-analysis with 11 included studies to assess the effect of TACE and preventive antiviral therapy on predicting clinical outcomes in HBV-related hepatocellula...
Source: Japanese Journal of Clinical Oncology - April 10, 2019 Category: Cancer & Oncology Source Type: research

How to optimize the therapeutic effect of free autogenous fibula graft and wrist arthroplasty for giant cell tumors of distal radius?
ConclusionStrict surgical resection boundary and solid reconstruction of wrist joint capsule are the key to achieving excellent oncological prognosis and function of distal radius GCT. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - April 3, 2019 Category: Cancer & Oncology Source Type: research

The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view
ConclusionsOur study identified the highly lethal mutation combination cases and characterized the possible prognostic genes in Ewing sarcoma from a network perceptive. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - March 30, 2019 Category: Cancer & Oncology Source Type: research

NLRP7 and KHDC3L variants in Chinese patients with recurrent hydatidiform moles
ConclusionsGenotyping can be used to differentiate biparental complete moles from androgenetic moles and to predict the risk of recurrent moles in future pregnancies.NLRP7 c.1441 G>A may associate with biparental complete moles. Biparental complete moles exhibit genetic heterogeneity. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - March 28, 2019 Category: Cancer & Oncology Source Type: research

Osimertinib for patients with EGFR T790M mutation-positive non –small-cell lung cancer and a poor performance status
ConclusionsOsimertinib therapy demonstrates promising efficacy and acceptable safety in patients withEGFR T790M mutation-positive NSCLC who have poor PS. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - March 28, 2019 Category: Cancer & Oncology Source Type: research

Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study
ConclusionCombination chemotherapy consisting of carboplatin plus S-1 and concurrent TRT had a promising efficacy in elderly patients with locally advanced NSCLC; however, radiation pneumonitis was frequently observed. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - March 27, 2019 Category: Cancer & Oncology Source Type: research

In this issue
(Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - March 7, 2019 Category: Cancer & Oncology Source Type: research

Prostate cancer incidence rates in the world from the Cancer Incidence in Five Continents XI
(Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - July 11, 2018 Category: Cancer & Oncology Source Type: research

Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan
ConclusionsThe Eastern Cooperative Oncology Group performance status at presentation, C-reactive protein level and response to prior chemotherapy were prognostic factors for metastatic urothelial carcinoma patients undergoing second-line chemotherapy. In the future, this information might help guide the choice of salvage treatment, such as second-line chemotherapy or immune checkpoint inhibitors, after the failure of first-line chemotherapy. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 25, 2018 Category: Cancer & Oncology Source Type: research

The investigation study using a questionnaire about the employment of Japanese breast cancer patients
ConclusionsIn adjuvant treatment groups, in which quit rate was highest at the time of diagnosis, consultation about working is necessary immediately after diagnosis. Patients treated most heavily had higher quit rates and experienced more anxiety about working. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 25, 2018 Category: Cancer & Oncology Source Type: research

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study
AbstractBackgroundShorter duration of infusion of monoclonal antibody treatments may reduce treatment burden and improve healthcare resource utilization.MethodsThis phase II study recruited Japanese patients with previously untreated CD20+ B-cell non-Hodgkin lymphoma. Patients received intravenous obinutuzumab 1000 mg by regular infusion on Days 1, 8 and 15 of Cycle 1, followed by 90-min shorter duration of infusion in up to seven subsequent cycles, provided they received ≥3 regular infusions without any grade ≥3 infusion-related reactions and had a lymphocyte count
Source: Japanese Journal of Clinical Oncology - June 22, 2018 Category: Cancer & Oncology Source Type: research

Palliative pain relief and safety of percutaneous radiofrequency ablation combined with cement injection for bone metastasis
AbstractPurposeTo investigate the pain relief effect and safety of percutaneous radiofrequency ablation (RFA) with a multitined electrode combined with cement injection in patients with painful metastatic bone tumors.Materials and methodsSixteen patients with 34 osteolytic metastatic lesions were treated with RFA including 4 males and 12 females (age range 54 –84). Thirteen patients with spinal metastases received additional cement injection. Medical imaging, a visual analog scale (VAS) and the EORTC QLQ-C30 were performed to evaluate the metastatic lesion, pain and quality of life, respectively, before and after RFA...
Source: Japanese Journal of Clinical Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

Incidence and location of positive surgical margin among open, laparoscopic and robot-assisted radical prostatectomy in prostate cancer patients: a single institutional analysis
ConclusionsRobot-assisted radical prostatectomy may potentially achieve the lowest positive surgical margin rate among three surgical approaches. The bladder neck was the most common location of positive surgical margin in robot-assisted radical prostatectomy and apex in open radical prostatectomy and laparoscopic radical prostatectomy. Although robot-assisted radical prostatectomy may contribute to the reduction of positive surgical margin, dissection of the bladder neck requires careful attention to avoid positive surgical margins. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 19, 2018 Category: Cancer & Oncology Source Type: research

Factors predicting biochemical recurrence after radical prostatectomy among patients with clinical T3 prostate cancer
AbstractBackgroundThe effectiveness of cancer control is unclear after radical prostatectomy for patients with clinical T3 prostate cancer.MethodsWe retrospectively reviewed 1409 patients who underwent radical prostatectomy between April 2007 and December 2014, including 210 patients with cT3 prostate cancer. Nine patients who received neoadjuvant hormonal therapy and three patients who were lost to follow-up were excluded from the analysis. Clinical staging was performed by an experienced radiologist using preoperative magnetic resonance imaging findings. We analyzed the predictors of biochemical recurrence using Cox prop...
Source: Japanese Journal of Clinical Oncology - June 19, 2018 Category: Cancer & Oncology Source Type: research

Prognostic factors of non-ampullary duodenal adenocarcinoma
ConclusionAdvanced non-ampullary duodenal adenocarcinoma has a poor prognosis, but chemotherapy possibly improves the prognosis in the patients with recurrent non-ampullary duodenal adenocarcinoma. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 19, 2018 Category: Cancer & Oncology Source Type: research

Characteristic response to carboplatin plus paclitaxel protein-bound after pembrolizumab
(Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 13, 2018 Category: Cancer & Oncology Source Type: research

Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study)
This study aimed to confirm the superiority of early administration of first-line rituximab in terms of event-free survival to watchful waiting for stages III and IV follicular lymphoma with low tumour burden. A total of 290 patients will be accrued from 50 Japanese institutions within 5 years. The primary endpoint is event-free survival defined as the period from registration to diagnosis of high tumour burden, therapy using cytotoxic chemotherapy and/or radiotherapy, or death. The secondary endpoints are overall survival, progression-free survival, cytotoxic chemotherapy/radiotherapy-free survival, histological transform...
Source: Japanese Journal of Clinical Oncology - June 13, 2018 Category: Cancer & Oncology Source Type: research

New developments in systemic therapy for advanced biliary tract cancer
AbstractBiliary tract cancer, carcinoma of the extrahepatic bile ducts, carcinoma of the gall bladder, ampullary carcinoma and intrahepatic cholangiocarcinoma are often identified at an advanced stage and have poor prognoses. Although effective chemotherapy regimens are needed, their development remains unsatisfactory. From the results of a phase III clinical trial (ABC-02 trial), gemcitabine plus cisplatin is the standard first-line chemotherapeutic regimen for advanced biliary tract cancer. A phase III trial of gemcitabine plus cisplatin vs. gemcitabine plus S-1 therapy (FUGA-BT) demonstrated the non-inferiority of gemci...
Source: Japanese Journal of Clinical Oncology - June 11, 2018 Category: Cancer & Oncology Source Type: research

Effect of continuous intravenous oxycodone infusion in opioid-na ïve cancer patients with dyspnea
ConclusionContinuous oxycodone infusion could be a reasonable treatment option in the management of dyspnea in opioid-na ïve cancer patients. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 11, 2018 Category: Cancer & Oncology Source Type: research

Mucositis with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of randomized controlled trials
AbstractBackgroundThe mucositis of anti-epidermal growth factor receptor monoclonal antibodies was poorly understood. We conducted this systematic review to fully investigate the mucositis of anti-epidermal growth factor receptor monoclonal antibodies in cancer patients.Study designEMBASE, MEDLINE and PubMed were searched for articles published till December 2017. The relevant randomized controlled trials in cancer patients treated with anti-epidermal growth factor receptor monoclonal antibodies were retrieved and the systematic evaluation was conducted.ResultsThirty-six randomized controlled trials and 15,364 patients wer...
Source: Japanese Journal of Clinical Oncology - June 11, 2018 Category: Cancer & Oncology Source Type: research

Prevalence and molecular characteristics of defective mismatch repair epithelial ovarian cancer in a Japanese hospital-based population
ConclusionsThe prevalence of defective mismatch repair epithelial ovarian cancer in the Japanese hospital-based population was extremely low. Molecular mechanism involved in such defective mismatch repair ovarian cancers seems to be epigenetic events throughMLH1 promotor hypermethylation or somatically mutated mismatch repair genes without germline mismatch repair mutation. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 8, 2018 Category: Cancer & Oncology Source Type: research